Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand
Authors: Douglas S. Walsh
Sornchai Looareesuwan
Polrat Wilairatana
D. Gray Heppner
Douglas B. Tang
Thomas G. Brewer
Watcharee Chokejindachai
Parnpen Viriyavejakul
Dennis E. Kyle
Wilbur K. Milhous
Brian G. Schuster
John Horton
David J. Braitman
Ralf P. Brueckner
Mahidol University
Walter Reed Army Institute of Research
U.S. Army Medical Materiel Development Activity
GlaxoSmithKline plc.
Keywords: Immunology and Microbiology;Medicine
Issue Date: 1-Dec-1999
Citation: Journal of Infectious Diseases. Vol.180, No.4 (1999), 1282-1287
Abstract: WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n = 15) received 300 mg daily for 7 days; group B (n = 11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n = 9), 1 dose of 500 mg. A fourth group (D; n = 9) received chloroquine only. Among patients who completed 2-6 months of follow-up (n = 23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse.
ISSN: 00221899
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.